biotech · Acute Myeloid Leukemia · Sarcoma,Soft Tissue · MBRX
Moleculin Biotech
Moleculin Biotech clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Houston, USA
- Founded
- 2006
- Employees
- 22
- Programs
- 9
- Drugs
- 10
- Patents
- 1
Moleculin Biotech projects
5 ClinicalTrials.gov programs sponsored by Moleculin Biotech.
Moleculin Biotech has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Liposomal Annamycin
Moleculin Biotech
Leukemia, Myeloid, Acute
3 trials -
Liposomal Annamycin (L-Annamycin)
Moleculin Biotech
Sarcoma,Soft Tissue
1 trial -
MB-106
Moleculin Biotech
Acute Myeloid Leukemia
1 trial -
MOL4239
Moleculin Biotech
Psoriasis
1 trial -
STAT3 Inhibitor WP1066
Moleculin Biotech
Glioblastoma, IDH-Wildtype
1 trial
Frequently asked questions
How many clinical projects does Moleculin Biotech have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.